LambdaVision’s signature product — an artificial retina that could change the lives of thousands with degenerative eye diseases — is under development aboard the International Space Station. The theory is that the microgravity of the space station could be the best place to actually manufacture the tiny, layered protein device LambdaVision hopes to implant in the back of the human eye.
The concept comes from the work of Robert Birge, a UConn chemistry professor and innovator in the field of light sensitive proteins. Today, he’s a member of the firm’s board of directors and carries the title of founder.